Beone Medicines Ltd. (ONC) hisse senedi — iyi bir şirket mi?

Beone Medicines Ltd. (ONC) hisse senedi — iyi bir şirket mi? — InspectStocks

Nasıl para kazanıyor

Sales of cancer medicines%98

Gelir payları Q1 2026 dönemi için tahmindir; resmî bir bildirimden alınmış rakamlar değildir.

Rekabet ettiği şirketler

Ne satıyor6

BRUKINSA (zanubrutinib)
A pill for several blood cancers that blocks Bruton tyrosine kinase, a protein that helps certain cancer cells grow.
TEVIMBRA (tislelizumab)
An antibody treatment that blocks a signal cancer cells use to reduce the immune system's attack on them.
BEQALZI (sonrotoclax)
A pill that blocks the B-cell lymphoma 2 protein, which can help cancer cells survive; it is approved in the United States for certain mantle cell lymphoma patients.

3 tane daha göster

XGEVA (denosumab)
An antibody medicine marketed by BeOne in China to help prevent bone complications in people with cancer and to treat giant cell tumor of bone.
BLINCYTO (blinatumomab)
A medicine marketed by BeOne in China for acute lymphoblastic leukemia that helps immune cells recognize and attack cancer cells.
KYPROLIS (carfilzomib)
A medicine marketed by BeOne in China for multiple myeloma that interferes with a process cancer cells use to dispose of unwanted proteins.

Kim alıyor2

Commercial distributors and other medicine buyers purchase BeOne's products for sale or supply to treatment providers.
Government health systems and private insurers decide which medicines they cover and reimburse; patients receive the medicines through their cancer care.

Neye dayanıyor ve onu ne yıkabilir

Faaliyetin dayandığı şeyler

1A large share of sales comes from BRUKINSA, so its continued use by doctors and patients and its coverage by health systems and insurers matter to revenue.
2Sales depend on government and private reimbursement, including coverage decisions and negotiated medicine prices in China and other markets.
3For licensed medicines such as XGEVA, BLINCYTO and KYPROLIS, BeOne depends on partner agreements and partner or contract manufacturers for supply.
4BeOne relies on some outside manufacturers, suppliers and research contractors for medicines, materials and development work.

Ters gidebilecekler

1Clinical trials may not show that medicines work or are safe enough for regulators to approve them; delays, trial failures or safety problems could prevent new medicines or uses from reaching patients.
2Competition from medicines such as IMBRUVICA, CALQUENCE and KEYTRUDA, along with changes in coverage, reimbursement or medicine pricing, could reduce sales or patient access.
3BeOne operates across China, the United States and other markets, so changes in government policy, regulation or trade relations can affect approvals, manufacturing, sales and the movement of money.

Tüm finansal tablolar →

Beone Medicines Ltd. hakkında

BeOne Medicines discovers, develops, makes and sells treatments for cancer. Its main medicine, BRUKINSA (zanubrutinib), is a pill that blocks Bruton tyrosine kinase, a protein involved in some blood cancers. It also sells TEVIMBRA, an antibody that blocks a signal cancers use to dampen immune attacks, and markets licensed cancer medicines in China.

Merkez: Basel, Switzerland
Kuruluş: 2010
Çalışan sayısı: More than 12,000 (Q2 2026, medium)
İşlem gördüğü borsa: Nasdaq
Mali yıl sonu: December 31

Beone Medicines Ltd. şirketinin ABD Menkul Kıymetler ve Borsa Komisyonu’na (SEC) sunduğu kendi belgelerinden kuruldu. Rakamlar bildirildiği gibidir; hisse başına geçmiş bugünkü hisse tabanına göre yeniden hesaplanmıştır. Bu bir işletmeyi anlatır — yatırım tavsiyesi değildir ve alma ya da satma önerisi değildir.

Keep exploring

The themes Beone Medicines is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.

Highest-graded in Biotechnology

Graded A or B and worth $2B or more: A first, then the largest.

Grade rose recently in Healthcare

Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.

Nasıl para kazanıyor

Sales of cancer medicines%98

Gelir payları Q1 2026 dönemi için tahmindir; resmî bir bildirimden alınmış rakamlar değildir.

Rekabet ettiği şirketler

Ne satıyor6

BRUKINSA (zanubrutinib)
A pill for several blood cancers that blocks Bruton tyrosine kinase, a protein that helps certain cancer cells grow.
TEVIMBRA (tislelizumab)
An antibody treatment that blocks a signal cancer cells use to reduce the immune system's attack on them.
BEQALZI (sonrotoclax)
A pill that blocks the B-cell lymphoma 2 protein, which can help cancer cells survive; it is approved in the United States for certain mantle cell lymphoma patients.

3 tane daha göster

XGEVA (denosumab)
An antibody medicine marketed by BeOne in China to help prevent bone complications in people with cancer and to treat giant cell tumor of bone.
BLINCYTO (blinatumomab)
A medicine marketed by BeOne in China for acute lymphoblastic leukemia that helps immune cells recognize and attack cancer cells.
KYPROLIS (carfilzomib)
A medicine marketed by BeOne in China for multiple myeloma that interferes with a process cancer cells use to dispose of unwanted proteins.

Kim alıyor2

Commercial distributors and other medicine buyers purchase BeOne's products for sale or supply to treatment providers.
Government health systems and private insurers decide which medicines they cover and reimburse; patients receive the medicines through their cancer care.

Neye dayanıyor ve onu ne yıkabilir

Faaliyetin dayandığı şeyler

1A large share of sales comes from BRUKINSA, so its continued use by doctors and patients and its coverage by health systems and insurers matter to revenue.
2Sales depend on government and private reimbursement, including coverage decisions and negotiated medicine prices in China and other markets.
3For licensed medicines such as XGEVA, BLINCYTO and KYPROLIS, BeOne depends on partner agreements and partner or contract manufacturers for supply.
4BeOne relies on some outside manufacturers, suppliers and research contractors for medicines, materials and development work.

Ters gidebilecekler

1Clinical trials may not show that medicines work or are safe enough for regulators to approve them; delays, trial failures or safety problems could prevent new medicines or uses from reaching patients.
2Competition from medicines such as IMBRUVICA, CALQUENCE and KEYTRUDA, along with changes in coverage, reimbursement or medicine pricing, could reduce sales or patient access.
3BeOne operates across China, the United States and other markets, so changes in government policy, regulation or trade relations can affect approvals, manufacturing, sales and the movement of money.

Tüm finansal tablolar →

Beone Medicines Ltd. hakkında

Merkez: Basel, Switzerland
Kuruluş: 2010
Çalışan sayısı: More than 12,000 (Q2 2026, medium)
İşlem gördüğü borsa: Nasdaq
Mali yıl sonu: December 31

Nasıl para kazanıyor

Rekabet ettiği şirketler

Ne satıyor6

Kim alıyor2

Neye dayanıyor ve onu ne yıkabilir

Faaliyetin dayandığı şeyler

Ters gidebilecekler

Beone Medicines Ltd. hakkında

Keep exploring

Highest-graded in Biotechnology

Grade rose recently in Healthcare

Nasıl para kazanıyor

Rekabet ettiği şirketler

Ne satıyor6

Kim alıyor2

Neye dayanıyor ve onu ne yıkabilir

Faaliyetin dayandığı şeyler

Ters gidebilecekler

Beone Medicines Ltd. hakkında

Keep exploring

Highest-graded in Biotechnology

Grade rose recently in Healthcare

Beone Medicines Ltd.

Q3 2026 results

Revenue

EPS, GAAP

Operating income, GAAP

Company outlook

Büyüme ve nakit — 5 üzerinden 5

İş eğilimi

Zaman içinde hisse fiyatı ve not

Nasıl para kazanıyor

Rekabet ettiği şirketler

Ne satıyor6

Kim alıyor2

Neye dayanıyor ve onu ne yıkabilir

Faaliyetin dayandığı şeyler

Ters gidebilecekler

Beone Medicines Ltd. hakkında

Keep exploring

Highest-graded in Biotechnology

Grade rose recently in Healthcare

Nasıl para kazanıyor

Rekabet ettiği şirketler

Ne satıyor6

Kim alıyor2

Neye dayanıyor ve onu ne yıkabilir

Faaliyetin dayandığı şeyler

Ters gidebilecekler

Beone Medicines Ltd. hakkında

Keep exploring

Highest-graded in Biotechnology

Grade rose recently in Healthcare

Beone Medicines Ltd.

Geçmiş getiri

Q3 2026 results

Revenue

EPS, GAAP

Operating income, GAAP

Company outlook

Büyüme ve nakit — 5 üzerinden 5

İş eğilimi

Zaman içinde hisse fiyatı ve not